Health Infrastructure is planning for the new RNA Research and Pilot Manufacturing Facility that will enable research, development and production of a broad spectrum of RNA technologies locally.
OVERVIEW
The new facility will conduct small-scale production of messenger RNA (mRNA), synthetic RNA (sRNA) and lipid nanoparticles (LNP) encapsulation at a scale which will enable clinical trials of new therapeutics.
Viruses, cancers, genetic diseases and many other health-related issues are potentially treatable with RNA technologies.
Similar in structure to DNA, RNA is a nucleic acid found in every cell of the body, which transmits genetic information between DNA and proteins to control the amount and type of protein made within a cell. RNA can also help to turn genes on and off, aid chemical reactions, regulate cell behaviour and inhibit other RNAs.
The NSW Government has committed $72.2 million to build the RNA Research and Pilot Manufacturing Facility, as part of a total $95.8 commitment for the facility.
A further $119 million has been announced over 10 years for RNA research and development initiatives.
The new facility will be located in the Connect Innovation Precinct at Macquarie University and operated by Myeloid Therapeutics, a global therapeutics company.
BENEFITS
The project will:
- Be the first opportunity for RNA research and development to be tested and developed locally, across the broad spectrum of RNA technology, reducing Australia’s reliance on international supply
- Provide Australian patients with faster access to new and innovative RNA therapeutics to treat diseases such as cancer and rare genetic diseases
- Attract global industry investment to Australia, foster local jobs and skills and secure domestic-market access to future therapeutics
- Be central to NSW’s thriving RNA research and development ecosystem, surrounded by medical and research facilities, existing infrastructure, and world-leading RNA and cell and gene therapy expertise
- Boost innovation and technology in NSW, centralise RNA knowledge and expertise, create highly skilled jobs, and help NSW become a global leader in RNA research and production
- Capitalise on NSW’s competitive advantage by translating its strengths in research and development into a sustainable commercial pipeline of RNA therapeutics and products.
For more information read:
Contact the project team for futher enquiries via
HI-RNA@health.nsw.gov.au.